Comparison of screen detected and clinically diagnosed prostate cancer in the European Randomized study of Screening for Prostate Cancer, section Rotterdam

Journal of Urology

Volumn 174, Issue 1, 2005, Pages 121-125

  Van Der Cruijsen Koeter, Ingrid W ^a   Vis, André N ^b   Roobol, Monique J ^a   Wildhagen, Mark F ^a   De Koning, Harry J ^a   Van Der Kwast, Theo H ^b   Schröder, Fritz H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

Author keywords

Mass screening; Prognosis; Prostate; Prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER REGISTRY; CANCER SCREENING; CLINICAL EXAMINATION; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGITAL RECTAL EXAMINATION; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; TRANSRECTAL ULTRASONOGRAPHY;

EID: 20444459458     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000162061.40533.0f     Document Type: Article

References (15)

1. de Koning, H. J., Liem, M. K., Baan, C. A., Boer, R., Schroder, F. H. and Alexander, F. E.: Prostate cancer mortality reduction by screening: power and time frame with complete enrollment in the European Randomised study of Screening for Prostate Cancer (ERSPC) trial. Int J Cancer, 98: 268, 2002
2. Auvinen, A., Rietbergen, J. B., Denis, L. J., Schroder, F. H. and Prorok, P. C.: Prospective evaluation plan for randomised trials of prostate cancer screening. The International Prostate Cancer Screening Trial Evaluation Group. J Med Screening, 3: 97, 1996
3. Beemsterboer, P. M., Kranse, R., de Koning, H. J., Habbema, J. D. and Schroder, F. H.: Changing role of three screening modalities in the European Randomized Study of Screening for Prostate Cancer (Rotterdam). Int J Cancer, 84: 437, 1999
4. Schroder, F. H., van der Maas, P., Beemsterboer, P., Kruger, A. B., Hoedemaeker, R., Rietbergen, J. et al: Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst, 90: 1817, 1998
5. Rietbergen, J. B. W., Boeken Kruger, A. E., Hoedemaeker, R. F., Bangma, C. H., Kirkels, W. J. and Schroder, F. H.: Repeat screening for prostate cancer after 1-year followup in 984 biopsied men: clinical and pathological features of detected cancer. J Urol, 160: 2121, 1998
6. Krumholz, J. S., Carvalhal, G. F., Ramos, C. G., Smith, D. S., Thorson, P., Yan, Y. et al: Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features. Urology, 60: 469, 2002
7. Hugosson, J., Aus, G., Lilja, H., Lodding, P. and Pihl, C.: Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurements to detect prostate carcinoma. Cancer, 100: 1397, 2004
8. Corriere, J. N., Jr., Cornog, J. L. and Murphy, J. J.: Prognosis in patients with carcinoma of the prostate. Cancer, 25: 911, 1970
9. Beemsterboer, P. M. M., de Koning, H. J., Kranse, R., Trienekens, P. H., van der Maas, P. J. and Schröder, F. H.: Prostate specific antigen testing and digital rectal examination before and during a randomized trial of screening for prostate cancer: European Randomized Study of Screening for Prostate Cancer, Rotterdam. J Urol, 164: 1216, 2000
10. Otto, S. J., van der Cruijsen, I. W., Liem, M. K., Korfage, I. J., Schroder, F. H. and de Koning, H. J.: Effective PSA contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. Int J Cancer, 105: 394, 2003
11. Visser, O., Coebergh, J. W. W., Schouten, L. J. and van Dijck, J. A. A. M.: Incidence of cancer in the Netherlands 1994: the sixth report of the Netherlands Cancer Registry.
12. Etzioni, R., Penson, D. F., Legler, J. M., di Tommaso, D., Boer, R., Gann, P. H. et al: Overdiagnosis due to prostate-specific antigen screening: lessons from U. S. prostate cancer incidence trends. J Natl Cancer Inst, 94: 981, 2002
13. Schröder, F. H., van der Cruijsen-Koeter, I., de Koning, H. J., Vis, A. N., Hoedemaeker, R. F. and Kranse, R.: Prostate cancer detection at low prostate specific antigen. J Urol, 163: 806, 2000
14. Draisma, G., Boer, R., Otto, S. J., van der Cruijsen, I. W., Damhuis, R. A., Schroder, F. H. et al: Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst, 95: 868, 2003
15. Van der Cruijsen-Koeter, I. W., van der Kwast, T. H. and Schroder, F. H.: Interval carcinomas in the European Randomized Study of Screening for Prostate Cancer (ERSPC)-Rotterdam. J Natl Cancer Inst, 95: 1462, 2003